You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCapromab
Accession NumberDB00089  (BTD00080, BIOD00080)
TypeBiotech
GroupsApproved
Description

Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA. Pendetide acts as a chelating agent for the radionuclide indium-111. Capromab is used to image the extent of prostate cancer.

Protein structureDb00089
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Prostascint Kit for The Preparation Of Indium In 111 Capromab PendetidekitJazz Pharmaceuticals, Inc.1996-10-28Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ProstaScintCytogen Corp.
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Capromab pendetide
145464-28-4
ThumbNot applicableDBSALT001832
Categories
UNIILZM5W2UC3I
CAS number151763-64-3
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor diagnosis of prostate cancer and detection of intra-pelvic metastases.
PharmacodynamicsBinds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.
Mechanism of actionBinds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 4 ± 2.1 L
Protein bindingNot Available
Metabolism

Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production

Route of eliminationApproximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.
Half lifeNot Available
Clearance
  • 42 +/- 22 mL/hr
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit
Prices
Unit descriptionCostUnit
Prostascint kit1584.0USD kit
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point61 °C (FAB fragment), 71 °C (whole mAb)Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000)
References
Synthesis ReferenceNot Available
General References
  1. Link [Link]
  2. Link [Link]
  3. Link [Link]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelDownload (1.65 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneAbiraterone may decrease effectiveness of Capromab as a diagnostic agent.
BetamethasoneBetamethasone may decrease effectiveness of Capromab as a diagnostic agent.
BicalutamideBicalutamide may decrease effectiveness of Capromab as a diagnostic agent.
BuserelinBuserelin may decrease effectiveness of Capromab as a diagnostic agent.
CetrorelixCetrorelix may decrease effectiveness of Capromab as a diagnostic agent.
CorticotropinCorticotropin may decrease effectiveness of Capromab as a diagnostic agent.
Cortisone acetateCortisone acetate may decrease effectiveness of Capromab as a diagnostic agent.
Cyproterone acetateCyproterone acetate may decrease effectiveness of Capromab as a diagnostic agent.
DegarelixDegarelix may decrease effectiveness of Capromab as a diagnostic agent.
DesogestrelDesogestrel may decrease effectiveness of Capromab as a diagnostic agent.
DexamethasoneDexamethasone may decrease effectiveness of Capromab as a diagnostic agent.
DrospirenoneDrospirenone may decrease effectiveness of Capromab as a diagnostic agent.
EnzalutamideEnzalutamide may decrease effectiveness of Capromab as a diagnostic agent.
EstradiolEstradiol may decrease effectiveness of Capromab as a diagnostic agent.
Estrone sulfateEstropipate may decrease effectiveness of Capromab as a diagnostic agent.
Ethinyl EstradiolEthinyl Estradiol may decrease effectiveness of Capromab as a diagnostic agent.
Ethynodiol diacetateEthynodiol may decrease effectiveness of Capromab as a diagnostic agent.
FludrocortisoneFludrocortisone may decrease effectiveness of Capromab as a diagnostic agent.
FlutamideFlutamide may decrease effectiveness of Capromab as a diagnostic agent.
GanirelixGanirelix may decrease effectiveness of Capromab as a diagnostic agent.
GoserelinGoserelin may decrease effectiveness of Capromab as a diagnostic agent.
HistrelinHistrelin may decrease effectiveness of Capromab as a diagnostic agent.
HydrocortisoneHydrocortisone may decrease effectiveness of Capromab as a diagnostic agent.
KetoconazoleKetoconazole may decrease effectiveness of Capromab as a diagnostic agent.
LeuprolideLeuprolide may decrease effectiveness of Capromab as a diagnostic agent.
Medroxyprogesterone acetateMedroxyprogesterone Acetate may decrease effectiveness of Capromab as a diagnostic agent.
Megestrol acetateMegestrol acetate may decrease effectiveness of Capromab as a diagnostic agent.
MestranolMestranol may decrease effectiveness of Capromab as a diagnostic agent.
MethylprednisoloneMethylprednisolone may decrease effectiveness of Capromab as a diagnostic agent.
NafarelinNafarelin may decrease effectiveness of Capromab as a diagnostic agent.
NilutamideNilutamide may decrease effectiveness of Capromab as a diagnostic agent.
NorethisteroneNorethindrone may decrease effectiveness of Capromab as a diagnostic agent.
NorgestimateNorgestimate may decrease effectiveness of Capromab as a diagnostic agent.
PrednisolonePrednisolone may decrease effectiveness of Capromab as a diagnostic agent.
PrednisonePrednisone may decrease effectiveness of Capromab as a diagnostic agent.
Repository corticotropinRepository corticotropin may decrease effectiveness of Capromab as a diagnostic agent.
TriamcinoloneTriamcinolone may decrease effectiveness of Capromab as a diagnostic agent.
TriptorelinTriptorelin may decrease effectiveness of Capromab as a diagnostic agent.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
other/unknown
General Function:
Tetrahydrofolyl-poly(glutamate) polymer binding
Specific Function:
Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Isoform PSM-4 and isoform PSM-5 would...
Gene Name:
FOLH1
Uniprot ID:
Q04609
Molecular Weight:
84330.015 Da
References
  1. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, Navarro V, Hunter CJ, Bastidas D, Bander NH: In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000 Sep 15;60(18):5237-43. [PubMed:11016653 ]
  2. Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G: Update on fused capromab pendetide imaging of prostate cancer. Clin Prostate Cancer. 2005 Mar;3(4):230-8. [PubMed:15882479 ]
  3. Gregorakis AK, Holmes EH, Murphy GP: Prostate-specific membrane antigen: current and future utility. Semin Urol Oncol. 1998 Feb;16(1):2-12. [PubMed:9508077 ]
  4. Sodee DB, Ellis RJ, Samuels MA, Spirnak JP, Poole WF, Riester C, Martanovic DM, Stonecipher R, Bellon EM: Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results. Prostate. 1998 Nov 1;37(3):140-8. [PubMed:9792131 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on May 03, 2016 12:13